7/105 sources · 5 publishersUpdated Oct 26, 23:37 UTC
Johnson & Johnson reports 75% tumor response and 77% PSA reduction in Phase 1 prostate cancer trial
Johnson & Johnson presented Phase 1 data for its oral RIPTAC drug JNJ‑6143 at the ESMO 2026 Congress. In the 50 mg cohort, 12 of 16 patients (75%) achieved a confirmed tumor response and 77% of patients showed at least a 50% drop in PSA levels. The company will advance the 50 mg dose into a Phase 2 study for metastatic castration‑resistant prostate cancer.
Why it matters
The company says the results support moving JNJ‑6143 into Phase 2, which could expand J&J’s oncology pipeline and drive future sales. Analysts at Leerink Partners called the data “immaculate” and highlighted a potentially best‑in‑class profile for the drug.
Key facts
- 1The Phase 1 trial evaluated a 50 mg once‑daily dose of JNJ‑6143. yahoo.com
- 212 of 16 patients with measurable disease achieved a confirmed complete or partial tumor response, a 75% overall response rate. yahoo.com
- 3Among 38 patients treated at the 50 mg dose, 77% experienced a confirmed PSA reduction of at least 50%. yahoo.com
- 4The median follow‑up period was 5.6 months. yahoo.com
- 5The most common treatment‑related adverse events were elevated cholesterol (18% of patients), nausea (16%), and increased triglycerides (16%). yahoo.com
- 6Johnson & Johnson plans a Phase 2 trial of JNJ‑6143 in metastatic prostate cancer, with recruitment having started on Sept. 16. econotimes.com
Open questions
- Material 5 reports a 69% confirmed tumor response among 31 patients, differing from the 75% response reported in materials 1‑4.
- Material 5 cites a 77% PSA reduction among 31 patients, while material 2 gives the same 77% figure for 38 patients.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.